Literature DB >> 7889969

Possible prevention of in vitro selection of resistant Streptococcus pneumoniae by beta-lactamase inhibitors.

H Carsenti-Etesse1, J Durant, F De Salvador, M Bensoussan, F Bensoussan, C Pradier, E Bernard, V Mondain, A Thabaut, P Dellamonica.   

Abstract

The development of resistance in vitro in five strains of Streptococcus pneumoniae (3 with full susceptibility and 2 with intermediate susceptibility to penicillin) was investigated by serial passages in the presence of subinhibitory concentrations of amoxicillin and ampicillin. At the end of passaging, MICs of antibiotics for all the strains increased by a factor of four or more, reaching at least intermediate levels. MICs of cephalosporins, ampicillin and amoxicillin increased for almost all variants obtained. Similar results were obtained with amoxicillin plus clavulanic acid at a ratio of 2:1 and at a constant concentration of 2 micrograms/ml, and with ampicillin plus sulbactam at a ratio 2:1. In contrast, no significant modification of MIC was seen with ampicillin plus sulbactam at a constant concentration of 4 micrograms/ml sulbactam. These results suggest interaction of sulbactam with penicillin binding proteins as described previously for other bacterial species, and merit further investigation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7889969     DOI: 10.1007/bf02111828

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  Factors associated with middle ear isolates of Streptococcus pneumoniae resistant to penicillin in a children's hospital.

Authors:  K L Ford; E O Mason; S L Kaplan; L B Lamberth; J Tillman
Journal:  J Pediatr       Date:  1991-12       Impact factor: 4.406

2.  In vitro effects of beta-lactams combined with beta-lactamase inhibitors against methicillin-resistant Staphylococcus aureus.

Authors:  S Kobayashi; S Arai; S Hayashi; T Sakaguchi
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

3.  Alterations in penicillin-binding proteins of clinical and laboratory isolates of pathogenic Streptococcus pneumoniae with low levels of penicillin resistance.

Authors:  S Handwerger; A Tomasz
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

4.  Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s.

Authors:  S Soares; K G Kristinsson; J M Musser; A Tomasz
Journal:  J Infect Dis       Date:  1993-07       Impact factor: 5.226

5.  Disk test for the differentiation of pneumococci from other alpha-hemolytic streptococci.

Authors:  V Lorian; G Markovits
Journal:  Appl Microbiol       Date:  1973-07

Review 6.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

7.  Concentrations of sulbactam/ampicillin in serum and lung tissue.

Authors:  U Frank; E Schmidt-Eisenlohr; A Joos-Württemberger; J Hasse; F Daschner
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

Review 8.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

Review 9.  Pneumonia. Patient profiles, choice of empiric therapy, and the place of third-generation cephalosporins.

Authors:  J M Leedom
Journal:  Diagn Microbiol Infect Dis       Date:  1992-01       Impact factor: 2.803

10.  The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio.

Authors:  M R Reichler; A A Allphin; R F Breiman; J R Schreiber; J E Arnold; L K McDougal; R R Facklam; B Boxerbaum; D May; R O Walton
Journal:  J Infect Dis       Date:  1992-12       Impact factor: 5.226

View more
  1 in total

1.  The population dynamics of antimicrobial chemotherapy.

Authors:  M Lipsitch; B R Levin
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.